PRGN-3006 targets CD33, which is highly overexpressed in myeloid leukemia cells and leukemic stem cells with limited expression outside the hematopoietic system. PRGN-3006 has been granted fast ...

One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation ... More information: Tobias ...

SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Blood Cancer. According to GlobalData, Phase I drugs for Blood Cancer have a 68% phase transition success rate ...

The researchers also found that changes in blood cell types across the lifetime can have important implications for blood cancers. They classified acute myeloid leukemia cells by their resemblance ...

The leukemia drug was based on Dr. Bernstein’s fundamental research ... This led to the development of Mylotarg®, a CD33-targeting antibody that carries a lethal drug to kill AML cells; Mylotarg is ...

investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3 ...

SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing healthy bone marrow cells. Three AML patients have ...